$ATXI
Avenue Therapeutics Inc

2021 Q4 Form 10-K Financial Statement

#000141057822000516 Filed on March 25, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $524.0K $2.484M $520.0K
YoY Change 0.77% 5.7% -16.13%
% of Gross Profit
Research & Development $390.0K $1.254M $480.0K
YoY Change -18.75% -56.25% -90.12%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $914.0K $1.254M $1.000M
YoY Change -8.6% -56.25% -81.72%
Operating Profit -$3.738M
YoY Change -28.29%
Interest Expense $1.000K $7.000K $10.00K
YoY Change -90.0% -88.33% -83.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$913.0K -$3.731M -$990.0K
YoY Change -7.78% -27.55% -81.73%
Income Tax
% Of Pretax Income
Net Earnings -$913.0K -$3.731M -$990.0K
YoY Change -7.78% -27.57% -81.73%
Net Earnings / Revenue
Basic Earnings Per Share -$0.22
Diluted Earnings Per Share -$50.03K -$0.22 -$59.78K
COMMON SHARES
Basic Shares Outstanding 18.70M 17.00M
Diluted Shares Outstanding 17.00M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.763M $3.763M $3.130M
YoY Change 20.22% 20.22% -64.23%
Cash & Equivalents $3.763M $3.763M $3.132M
Short-Term Investments
Other Short-Term Assets $107.0K $107.0K $110.0K
YoY Change -2.73% -2.73% -35.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.960M $3.960M $3.245M
YoY Change 22.03% 21.85% -63.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.960M $3.960M $3.245M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $3.960M $3.960M $3.245M
YoY Change 22.03% 21.85% -63.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $304.0K $304.0K $143.0K
YoY Change 112.59% 117.14% -59.14%
Accrued Expenses $205.0K $205.0K $740.0K
YoY Change -72.3% -72.3% -2.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $509.0K $509.0K $886.0K
YoY Change -42.55% -42.81% -58.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $509.0K $509.0K $886.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $509.0K $509.0K $886.0K
YoY Change -42.55% -42.81% -58.21%
SHAREHOLDERS EQUITY
Retained Earnings -$77.00M -$73.27M
YoY Change 5.09%
Common Stock $80.45M $75.63M
YoY Change 6.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.451M $3.451M $2.359M
YoY Change
Total Liabilities & Shareholders Equity $3.960M $3.960M $3.245M
YoY Change 22.03% 21.85% -63.62%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$913.0K -$3.731M -$990.0K
YoY Change -7.78% -27.57% -81.73%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.203M -$3.750M -$1.190M
YoY Change 1.09% -18.71% -76.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.044M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.381M 4.381M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.203M -3.750M -1.190M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 4.381M 4.381M 0.000
Net Change In Cash 3.178M 631.0K -1.190M
YoY Change -367.06% -111.24%
FREE CASH FLOW
Cash From Operating Activities -$1.203M -$3.750M -$1.190M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16997564
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16506447
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001644963
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21089658
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16747803
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38114
CY2021 dei Entity Registrant Name
EntityRegistrantName
AVENUE THERAPEUTICS, INC.
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
Delaware
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2021 dei City Area Code
CityAreaCode
781
CY2021 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
ATXI
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
16813403
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21732284
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
New York, NY
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3763000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3132000
CY2021Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
90000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
107000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
113000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
3960000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
3245000
CY2021Q4 us-gaap Assets
Assets
3960000
CY2020Q4 us-gaap Assets
Assets
3245000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
451000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
857000
CY2021Q4 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
58000
CY2020Q4 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
29000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
509000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
886000
CY2021Q4 us-gaap Liabilities
Liabilities
509000
CY2020Q4 us-gaap Liabilities
Liabilities
886000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21089658
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16747803
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
80448000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
75625000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76999000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73268000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3451000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2359000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3960000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3245000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1254000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2866000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2484000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3800000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2347000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-3738000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-5213000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
62000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-3731000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5151000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16997564
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16506447
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2359000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
442000
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4381000
CY2021 atxi Share Issued During Period Value Warrants Exercised
ShareIssuedDuringPeriodValueWarrantsExercised
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-3731000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3451000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6800000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
710000
CY2020 atxi Share Issued During Period Value Warrants Exercised
ShareIssuedDuringPeriodValueWarrantsExercised
0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-5151000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2359000
CY2021 us-gaap Profit Loss
ProfitLoss
-3731000
CY2020 us-gaap Profit Loss
ProfitLoss
-5151000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
442000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
710000
CY2021 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-90000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-57000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-406000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-244000
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
29000
CY2020 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
15000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3750000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4613000
CY2020 atxi Milestone Payment For Research And Development Licenses
MilestonePaymentForResearchAndDevelopmentLicenses
1000000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5044000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
663000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4381000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
631000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5613000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3132000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8745000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3763000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3132000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2016Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
250000
CY2016Q3 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.025
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1666356
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1389910
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26939000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
27800000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
26900000
CY2021 atxi Agreement Description Terms
AgreementDescriptionTerms
(i) issue annually to Fortress, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Avenue’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Fortress will be paid a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2021Q4 atxi Gross Proceeds From Issuance Initial Public Offering
GrossProceedsFromIssuanceInitialPublicOffering
2000000.0
CY2021Q4 atxi Number Of Period Options To Purchase Granted Underwriters
NumberOfPeriodOptionsToPurchaseGrantedUnderwriters
P45D
CY2021Q4 atxi Percentage Of Additional Common Stock Shares Issued To Underwriters
PercentageOfAdditionalCommonStockSharesIssuedToUnderwriters
0.15
CY2021Q4 atxi Number Of Period Options To Purchase Granted Underwriters
NumberOfPeriodOptionsToPurchaseGrantedUnderwriters
P45D
CY2021Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1800000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
304000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
143000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
24000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
23000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
123000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
691000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
451000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
857000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 atxi Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
2238805
CY2021Q4 us-gaap Share Price
SharePrice
1.34
CY2021Q4 atxi Gross Proceeds From Issuance Initial Public Offering
GrossProceedsFromIssuanceInitialPublicOffering
3000000.0
CY2021Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
2600000
CY2021Q4 atxi Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
1910100
CY2021Q4 us-gaap Share Price
SharePrice
1.07
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.13
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.13
CY2021 atxi Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent
0
CY2020 atxi Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.11
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.06
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.40
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23719000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22240000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
293000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
760000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1162000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1283000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
16000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2640000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2640000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27820000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26939000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27820000

Files In Submission

Name View Source Status
0001410578-22-000516-index-headers.html Edgar Link pending
0001410578-22-000516-index.html Edgar Link pending
0001410578-22-000516.txt Edgar Link pending
0001410578-22-000516-xbrl.zip Edgar Link pending
atxi-20211231.xsd Edgar Link pending
atxi-20211231x10k.htm Edgar Link pending
atxi-20211231x10k_htm.xml Edgar Link completed
atxi-20211231xex21d1.htm Edgar Link pending
atxi-20211231xex23d1.htm Edgar Link pending
atxi-20211231xex31d1.htm Edgar Link pending
atxi-20211231xex31d2.htm Edgar Link pending
atxi-20211231xex32d1.htm Edgar Link pending
atxi-20211231xex32d2.htm Edgar Link pending
atxi-20211231xex4d3.htm Edgar Link pending
atxi-20211231_cal.xml Edgar Link unprocessable
atxi-20211231_def.xml Edgar Link unprocessable
atxi-20211231_lab.xml Edgar Link unprocessable
atxi-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending